Celsion Corporation (NASDAQ:CLSN) has recently announced the latest translational data from the OVATION study of the Phase 1b dose clinical trials that combined GEN-1, Company’s 1L-12 gene-mediated immunotherapy, together with standard care for treatment of the lately-diagnosed patients of Stage 3 and 4 ovarian cancer. The patients went through the neoadjuvant chemotherapy (NACT) and afterwards […]
Celsion Corporation
Recent Stories
Energy Transfer (NYSE:ET) Invokes Force Majeure To Prevent Customers From Abandoning Expansion Of Dakota Access Pipeline
Oracle Corporation (NASDAQ:ORCL) Opens Second Oracle Cloud Infrastructure (OCI) Region In India
Will CBD Become Robinhood’s Next Focus? (YCBD, NEPT, MCTC, ACB, MJNA)
Macy’s Inc (NYSE:M) and J C Penney Company Inc (OTCMKTS:JCPNQ) To Consider Reinventing Their Business Operations
Intel Corp (NASDAQ:INTC) Acquires $253.5 Million Interest in Reliance Jio Platforms